Clinical trial NCT02319395: Behavioural Addiction and Genetics in Parkinson's Disease
Official title: Behavioural Addiction and Genetics in Parkinson's Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson Disease
Impulse Control Disorders
Keywords: Parkinson's Disease
Behaviour addiction
Dopamine agonist
Genetic.
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2014-12-18
Enrollment: 332
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: PD patients

Brief summary: The " Behavioural Addiction and Genetics in Parkinson's Disease " study (BADGE-PD) is a national (France), multicenter, genetic association, case-control study to identify genetic factors associated with behavioural addiction (or Impulse Control Disorders, ICD) related to dopamine agonists treatment in Parkinson's disease (PD). Polymorphisms of candidate genes supposed to be involved in this adverse effect will be compared in 200 PD patients with ICD (n=200) and 200 matched PD patients without ICD (n=200).

Detailed description: Objective: To identify susceptibility genes to impulse control disorders in Parkinson's Disease.

Study design: Genetic association study.

Primary objective:

To identify the susceptibility genes in behavior addiction in Parkinson's Disease

Secondary endpoints:

* To compare the clinical, neurological and psychiatric features of parkinsonian patients with behavior addiction compared to the control population. In case of differences between these groups, interaction will be studied with genetic factors
* Identify a psychometric profile from the TCI-R scale corresponding to the "hyperdopaminergic" subjects with AC personality

Patient selection:

Cases: patients with Parkinson's disease (PD) and impulse control disorder (ICD) as defined by a score greater than or equal to 2 or 3 scores greater than or equal to 2 at the "Evaluation Comportementale de la Maladie de Parkinson" scale (ECMP, Ardouin et al. 2009) for hyperdopaminergic items.

Controls: PD patients without impulse control disorder (ICD) as defined by a score of 0 or 1 at each hyperdopaminergic items AND no more than 2 items with a score of 1. Controls must have been treated with at least 300 mg of Levodopa equivalent daily dose for more than 12 months. Controls will be matched for sex, age, and age at onset of PD.

Number of subjects: 200 cases and 200 controls.

Clinical assessment: motor score (UPDRS), neuropsychological assessment, diagnostic criteria for addiction and ICD (MINI), self-administered psychometric questionnaire (TCI-R), treatment history, ICD history.

Genetic analysis: A blood sample will be taken for extraction and storage of DNA (DNA bank and Pitie-Salpetriere cells). Candidate genes\* and polymorphisms will be selected from the literature data (receptors, transporters and metabolizing enzymes monoamine) and the molecular signature induced by L-DOPA in the striatum of a mice model of PD.

Statistical analysis:

A two-step analysis will be performed. For the first step, a training set (36% of subjects) will be analyzed with a logistic regression model considering an additive genetic effect. For the second step, the top 27% of the more significant genetic markers will be analyzed by using the left over replication set (64% of patients). Finally, a pooled analysis will be performed.

Sample Size: 200 patients per group to study 50 candidate markers with a power of 83% for genotype effect of 2.0, an additive genetic model, each allele frequency of 0.5.

\* candidate genes list:

20 genes from the literature : DRD1, ANKK1, DRD2, DRD3, DRD4, DAT1, MAOA, COMT, HTR2A, HTR1B, TPH1, TPH2, 5HTT, GRIN2B, DBH, SCL6A2, BDNF, OPMR1, OPRK1, PDYN 8 genes from the experimentation: FosB, Arc, Nptx2, Ccrn4l, Car12, C8b, Mocs1, Mef2c

Eligibility criteria: Inclusion criteria :

Case Group

1. Age upper or equal to 30 years
2. Caucasian European (2 parents and 4 grandparents born in Europe)
3. Parkinson's disease according to the criteria of UKPDSBB
4. With a behavioral addiction defined as:

   * A score greater than or equal to 2 or 3 scores greater than or equal to 2 at hyperdopaminergic following items of Ardouin's scale (ECMP): eating behaviors, creativity, hobbyism, risk-taking behaviors, compulsive shopping, pathological gambling, hypersexuality, cyber-addiction, and Punding.
   * Onset under dopamine agonist or under L-DOPA
   * Present at the inclusion visit
   * OR in the past (\<6 years). For these patients, the scale of Ardouin must have been passed at the time of behavior trouble or within 3 months after its disappearance.
5. Affiliation to a social security
6. Signature of the consent form

Control Group

1. Age upper or equal to 30 years
2. Caucasian European (2 parents and 4 grandparents born in Europe)
3. Parkinson's disease according to the criteria of UKPDSBB
4. Time evolution of the disease than or equal to 5 years
5. Having taken during its evolution a dopamine agonist dose at least equivalent to 300 mg of L-DOPA for at least 12 months.
6. Not having behavioral addiction

   * Not current, defined as a score of 0 or 1 and at most two items with a score of 1 on all items above and addiction to L-DOPA.
   * Neither passed, given authenticated by the semi-structured interview retrospective finding a score of 0 or 1 on all items hyperdopaminergic of Ardouin's scale (see above) AND no more than two items with a score of 1 and addiction to L-DOPA.
7. Affiliation to a social security
8. Signature of the consent form

Exclusion criteria :

Case Group

1. No Parkinson's disease or atypical parkinsonian syndrome
2. Taking neuroleptic except clozapine for patients with AC
3. Behavioral Addiction having started BEFORE taking the antiparkinsonian treatment

Control Group

1. No Parkinson's disease or atypical parkinsonian syndrome
2. Taking neuroleptic included clozapine for control patients
3. Behavioral Addiction having started BEFORE taking the antiparkinsonian treatment
4. Patient with guardianship, deprived of his liberty by judicial decision

Primary outcomes:
measure: Allele frequency of 50 genetic markers (polymorphisms) will be compared between cases and controls.
timeFrame: baseline
Secondary outcomes:
measure: number of patients with a diagnostic of ICD according to the MINI
timeFrame: baseline
measure: Total UPDRS (Unified Parkinson's Disease Rating Scale) score
timeFrame: baseline
measure: Total score of the MMSE (Mini Mental State Examination)
timeFrame: baseline
measure: Sub scores at the temperament and Character Inventory (revised version, TCI-R)
timeFrame: baseline
measure: Number of subject in each group with personal or familial history of addiction
timeFrame: baseline
Other outcomes:
Locations:
city: Paris
country: France
facility: Groupe Hospitalier La Pitié Salpêtrière
Study officials:
affiliation: Assitance-Publique Hopitaux de Paris
name: jean-christophe Corvol, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: